Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Cho, Yeona ^a   Chang, Jee Suk ^a   Rha, Koon Ho ^a   Hong, Sung Joon ^a   Choi, Young Deuk ^a   Ham, Won Sik ^a   Kim, Jun Won ^a   Cho, Jaeho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADENOCARCINOMA; ADVERSE EFFECTS; AGED; BONE TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORGANS AT RISK; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; SECONDARY; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ORGANS AT RISK; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 84982166002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147191     Document Type: Article

References (32)

1. Adli M, Sevinc A, Kalender ME. Re: Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2006; 98: 364-365; author reply 365.
2. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 1655-1659. PMID: 11759643
3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358: 966-970. PMID: 11583750
4. Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004; 22: 3475-3484. PMID: 15337795
5. Nguyen DH, Truong PT, Alexander C, Walter CV, Hayashi E, Christie J, et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? Int J Radiat Oncol Biol Phys. 2012; 84: 39-45. doi: 10.1016/j.ijrobp.2011.11.046 PMID: 22330986
6. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006; 24: 2743-2749. PMID: 16702580
7. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184: 162-167. doi: 10.1016/j.juro.2010.03.034 PMID: 20483155
8. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10: 1081-1087. PMID: 22956807
9. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003; 169: 164-169. PMID: 12478127
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005. doi: 10.1056/NEJMoa1014618 PMID: 21612468
11. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006; 175: 27-34. PMID: 16406864
12. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002; 20: 3199-3205. PMID: 12149291
13. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004; 58: 862-870. PMID: 14967443
14. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366: 925-931. doi: 10.1056/NEJMoa1112824 PMID: 22397654
15. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 1124-1129. doi: 10.1016/j.ijrobp. 2007.11.044 PMID: 18313526
16. Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol. 2006; 79: 259-269. PMID: 16797094
17. McGrath SD, Antonucci JV, Fitch DL, Ghilezan M, Gustafson GS, Vicini FA, et al. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy. 2010; 9: 137-144. doi: 10.1016/j.brachy.2009.07.005 PMID: 19850537
18. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014; 6: 167-179. doi: 10.1177/1758834014529176 PMID: 25057303
19. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001; 61: 2207-2211. PMID: 11280788
20. Morgan SC, Parker CC. Local treatment of metastatic cancer-killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011; 8: 504-506. doi: 10.1038/nrclinonc.2011.88 PMID: 21647193
21. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438: 820-827. PMID: 16341007
22. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27: 1549-1556. doi: 10.1200/JCO.2008.17.0563 PMID: 19237635
23. Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010; 57: 754-761. doi: 10. 1016/j.eururo.2009.12.034 PMID: 20106588
24. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. PMID: 15470213
25. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422. doi: 10.1056/NEJMoa1001294 PMID: 20818862
26. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723. doi: 10.1056/NEJMoa1003466 PMID: 20525992
27. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53: 1111-1116. PMID: 12128109
28. Lee IJ, Seong J, Lee CG, Kim YB, Keum KC, Suh CO, et al. Early clinical experience and outcome of helical tomotherapy for multiple metastatic lesions. Int J Radiat Oncol Biol Phys. 2009; 73: 1517-1524. doi: 10.1016/j.ijrobp.2008.07.035 PMID: 19084348
29. Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol. 2015; 68: 325-334. doi: 10.1016/j.eururo.2014.07.020 PMID: 25108577
30. Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010; 28: 543-547. doi: 10.1007/s00345-010-0560-4 PMID: 20440505
31. Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Alexander C. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol. 2012; 19: 3028-3034. doi: 10.1245/s10434-012-2333-3 PMID: 22476751
32. Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int. 2013; 111: 697-699. doi: 10. 1111/bju.12087 PMID: 23578233